Lipigon Pharmaceuticals AB (OSTO:LPGO) EV-to-Revenue : 0.60 (As of Apr. 30, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lipigon Pharmaceuticals AB's enterprise value is kr9.92 Mil. Lipigon Pharmaceuticals AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr16.41 Mil. Therefore, Lipigon Pharmaceuticals AB's EV-to-Revenue for today is 0.60.

The historical rank and industry rank for Lipigon Pharmaceuticals AB's EV-to-Revenue or its related term are showing as below:

OSTO:LPGO' s EV-to-Revenue Range Over the Past 10 Years
Min: -7.56 Med: 4.93 Max: 23.3
Current: 0.6

During the past 6 years, the highest EV-to-Revenue of Lipigon Pharmaceuticals AB was 23.30. The lowest was -7.56. And the median was 4.93.

OSTO:LPGO's EV-to-Revenue is ranked better than
89.26% of 1034 companies
in the Biotechnology industry
Industry Median: 7.775 vs OSTO:LPGO: 0.60

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-30), Lipigon Pharmaceuticals AB's stock price is kr0.331. Lipigon Pharmaceuticals AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.10. Therefore, Lipigon Pharmaceuticals AB's PS Ratio for today is 3.34.

Lipigon Pharmaceuticals AB EV-to-Revenue Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB EV-to-Revenue Chart

Lipigon Pharmaceuticals AB Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

10.94

1.38

Lipigon Pharmaceuticals AB Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial												14.39	-	1.05	1.34	1.38

Competitive Comparison of Lipigon Pharmaceuticals AB's EV-to-Revenue

For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipigon Pharmaceuticals AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lipigon Pharmaceuticals AB's EV-to-Revenue falls into.

Lipigon Pharmaceuticals AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lipigon Pharmaceuticals AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	9.919	/	16.407
	=	0.60

Lipigon Pharmaceuticals AB's current Enterprise Value is kr9.92 Mil.
Lipigon Pharmaceuticals AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16.41 Mil.

Lipigon Pharmaceuticals AB (OSTO:LPGO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lipigon Pharmaceuticals AB's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.331	/	0.099
	=	3.34

Lipigon Pharmaceuticals AB's share price for today is kr0.331.
Lipigon Pharmaceuticals AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.10.

Lipigon Pharmaceuticals AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

9RP:Germany

Address

Tvistevagen 48 C, Umea, SWE, 90736

Website

https://www.lipigon.se

Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Headlines

No Headlines